iPremom
iPremom offers MaiRa, the first market test that evaluates preeclampsia risk from a blood sample as early as week 9 of pregnancy, under a gynecologist's prescription. The test provides early, personalized risk information to support medical decision-making and ongoing pregnancy monitoring, backed by clinical and scientific evidence. It is designed for pregnant women seeking early risk assessment and for gynecologists guiding prenatal care.
- Healthcare Technology
- Medical Devices
- Biotechnology
- Hardware
Funding
Raised to date
€15MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Est. $16.4Macross 1 round
€15M · Seed
Announced Sep 2026
Disclosed cumulative: $16.4M
Founders
Founder details are not available yet.
Product
Problem
Preeclampsia is a pregnancy complication that can appear without symptoms in its early stages, affecting both the mother and the baby. It occurs in 1 out of 20 pregnancies, contributes to 76,000 maternal deaths and 500,000 fetal deaths annually worldwide, and early detection is critical to prevent complications.
Solution
iPremom provides MaiRa, the first market test that evaluates preeclampsia risk from a blood sample as early as week 9 of pregnancy, under a gynecologist's prescription. The test delivers early, personalized risk information that supports medical decision-making and ongoing pregnancy monitoring. Developed by maternal-fetal health experts and based on clinical and scientific evidence, MaiRa enables proactive care, giving expectant mothers greater confidence and allowing clinicians to act before complications arise.
Target Audience
Primary users are pregnant women seeking early risk assessment and peace of mind, as well as gynecologists and healthcare professionals who prescribe the test and use its results to guide prenatal care and clinical decisions.
Features
- First market test to assess preeclampsia risk from week 9 of pregnancy using a blood sample
- Provides early, personalized risk information to support medical follow-up throughout pregnancy
- Developed by experts in maternal-fetal health and validated clinically and scientifically
- Designed to support medical decisions with evidence-based data
- Backed by a recent study published in Nature Medicine revealing key mechanisms behind preeclampsia, including a multi-omic map of the endometrium identifying glandular morphology alterations and proliferative stromal and epithelial cell phenotypes in preeclampsia patients